Cobicistat (GS-9350)
Cobicistat is a selective inhibitor of cytochrome P450 (CYP) 3A enzymes with IC50 values ranging from 0.03 to 0.285μM [1].
Cobicistat is a selective CYP3A inhibitor without intrinsic anti-HIV activity and is indicated in EU as a pharmacokinetic enhancer of the HIV-1 protease inhibitors atazanavir and darunavir in adults. Cobicistat is also developed to form a fixed-dose tablet in combination with elvitegravir, emtricitabine and TDF. Cobicistat inhibits CYP3A in vitro across a variety of substrates with IC50 values ranging from 0.03 to 0.285μM. Cobicistat is absorbed rapidly after oral administration in patients infected with HIV-1 with the Cmax of 1.2μg/ml. In the 48-week analysis of the phase III study, once-daily oral cobicistat is generally well tolerated. The tolerability of the cobicistat-boosted atazanavir remains similar longer term, with jaundice, ocular icterus and nausea in a 96-week analysis of the phase III study [1].
References:
[1] Deeks ED. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs. 2014 Feb;74(2):195-206.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 776.02 |
| Cas No. | 1004316-88-4 |
| Formula | C40H53N7O5S2 |
| Solubility | insoluble in H2O; ≥150.9 mg/mL in DMSO; ≥102.4 mg/mL in EtOH with ultrasonic |
| Chemical Name | thiazol-5-ylmethyl (5-(2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-yl)carbamate |
| SDF | Download SDF |
| Canonical SMILES | CC(C1=NC(CN(C(NC(C(NC(CC2=CC=CC=C2)CCC(NC(OCC3=CN=CS3)=O)CC4=CC=CC=C4)=O)CCN5CCOCC5)=O)C)=CS1)C |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Quality Control & MSDS
- View current batch:
Chemical structure
